RxDoctor Payments Data

Ebere Chukwu, MD

Advanced Heart Failure and Transplant Cardiology · Temple, TXNPI 1093908535

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $93,350 of the $114,546 with a category attached, or 81.5%. 17 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 53.0% of the total. Reporting peaked in 2023 at $48,717 and has fallen 91.1% since, to $4,353 in 2025.

$114,546in general payments, 2019–2025

Across 220 payments — averaging $520.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$61K
  • Boehringer Ingelheim$42K
  • Lilly USA, LLC$8K
  • Abbott$1K
  • Abiomed$795
  • Cvrx, Inc.$434
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$7,2206%
  • Speaking & faculty fees$93,35081%
  • Travel & lodging$7,7297%
  • Food & beverage$6,2045%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,546 in reported general payments places this provider in the 85th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

See all advanced heart failure and transplant cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$39,369
Medicare patients
139
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis34$780,108
EntrestoSacubitril/Valsartan274$309,390
JardianceEmpagliflozin256$261,650
OzempicSemaglutide81$86,663
FarxigaDapagliflozin Propanediol95$84,792
MounjaroTirzepatide11$11,337
Metoprolol Succinate279$7,503
Eplerenone24$2,806
Spironolactone301$2,740
Valsartan38$1,885
Atorvastatin Calcium107$1,525
Rosuvastatin Calcium51$1,340
Torsemide51$1,242
Carvedilol79$980
Losartan Potassium57$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$286$780,10834 claims
NovartisEntresto$413$309,390274 claims
Boehringer IngelheimJardiance$41,660$261,650256 claims
Novo NordiskOzempic$306$86,66381 claims
AstraZenecaFarxiga$373$84,79295 claims
Lilly USA, LLCMounjaro$7,615$11,33711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

Other advanced heart failure and transplant cardiology in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →